Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes

Younossi ZM, Stepanova M, Sulkowski MS, Naggie S, Puoti M, Orkin C, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis. 2015;212(3):367-377.

Publication Type:

Journal Article

Authors:

Z M Younossi; Stepanova, M.; M S Sulkowski; Naggie, S.; Puoti, M.; Orkin, C.; Hunt, S.L.

Source:

J Infect Dis, Volume 212, Issue 3, p.367-377 (2015)

Keywords:

analysis, Baltimore, clinical trial, Clinical Trials, coinfection, Disease, HCV, HCV coinfection, Health, hepatitis, Hepatitis C, hepatitis C virus, Hiv, Human, Infection, Italy, Liver, Liver Diseases, London, Maryland, Medicine, methods, Multivariate Analysis, North Carolina, Patients, Questionnaires, Research, Research Support, Ribavirin, sofosbuvir, treatment, Trust, Universities, Washington

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/25583164

Export Citation:

RIS Format

Top